Day: February 9, 2026

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeDanish Financial Supervisory AuthorityOther stakeholders Date        9 February 2026 Share buyback programme – week 6 The share buyback programme runs in the period 2 February 2026 up to and including 8 May 2026, see company announcement of 30 January 2026. During the period the bank will thus buy back its own shares for a total of up to DKK 500 million under the programme, but to a maximum of 600,000 shares. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme:Date Number of shares Average purchase price (DKK) Total purchased under the programme...

Schindellegi, Switzerland – 9 February 2026 Trifork Group AGCompany announcement no. 8/2026 Weekly report on share buyback On 22 December 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 23 December 2025 up to and including no later than 26 February 2026. For details, please see company announcement no. 58 of 22 December 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 219,735 treasury shares, corresponding to 1.1% of the share capital. Under the program, the following transactions...

Press contact:Mollie MellowsTel.:+ 44 73 42 70 93 84E-mail: mollie.mellows@capgemini.com Sovereign‑ready cloud and AI innovation set to scale for European enterprises with Capgemini solutions on the AWS Sovereign Cloud Paris, February 09, 2026 – Capgemini announced that its sovereign-ready cloud and AI solutions are available on the AWS European Sovereign Cloud, an independent cloud fully located and operated within the European Union (EU). Backed by Capgemini’s experience in secure transformation, risk management, and delivery of complex projects in highly regulated sectors, the partnership enables European clients to address fast-evolving digital sovereignty requirements while continuing to modernize and innovate. Across Europe, rapidly evolving sovereignty and data-control requirements are reshaping how organizations think about trust,...

LEADING EDGE MATERIALS AND ASCENSION EARTH RESOURCES TEAM UP ON HEAVY RARE EARTHS RECOVERY FROM NORRA KÄRR EUDIALYTEStrategic collaboration aims to assess innovative recovery methods for Heavy Rare Earth Elements (“HREE”) from Norra Kärr Eudialyte mineralisation. Leading Edge Materials 100% owned subsidiary Greenna Mineral AB and Ascension Earth Resources have entered into a Memorandum of Understanding. Both parties will negotiate in good faith toward a definitive collaboration agreement for a larger-scale pilot project, contingent on successful evaluation project outcomes.Vancouver, February 8, 2026 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) is pleased to announce that its 100% owned Swedish subsidiary Greenna Mineral AB (“GMAB”) has...

Banco Comercial Português, S.A. informs about Bank Millennium (Poland) preliminary unaudited results in 2025Attachment2026 02 09 Resultados Polónia_EN

Antwerp, Feb. 09, 2026 (GLOBE NEWSWIRE) — CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold two vessels, generating a capital gain of approximately 98.2 million USD in total. Euronav CMB.TECH has sold two VLCCs: Ingrid (2012, 314,000 dwt) and Ilma (2012, 314,000 dwt). The sale will generate a capital gain of approximately 98.2 million USD in Q2 2026, based on the net sales price and book values. The vessels will be delivered to their new owner in Q2 2026.  Announcement Q4 2025 results – 26 February 2026  About CMB.TECH  CMB.TECH is one of the largest listed, diversified and future-proof maritime groups in the world with a fleet of about 250 vessels: dry bulk vessels,  crude oil tankers, chemical tankers, container vessels, offshore wind vessels and port...

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)5 February 2026 13,000 950.45 12,355,8846 February 2026 12,327 970.06 11,957,921Accumulated under the programme 25,327 960.00 24,313,805Following settlement of the transactions...

BEIJING, Feb. 08, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538, a VAV1-directed molecular glue degrader (MGD). This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors, for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis....

TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China. The Priority Review and Approval Procedure was implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure,...